Oncology CRO Oversight FSP

To ensure compliance with the updated ICH E6 (R2) guidelines and to address internal capacity issues, a midsized biopharmaceutical Sponsor required qualified support to help ensure appropriate oversight of several large, global CRO providers. The Sponsor’s internal systems for oversight were adequate, but internal capacity proved insufficient, thereby choosing Catalyst as their 3rd party oversight partner.